Form 4: RxSight Director to Receive Future RSU Grant as Part of Compensation Plan

RxSight, Inc. Director Juliet Tammenoms Bakker is set to acquire 10,752 restricted stock units on June 3, 2025, as part of her compensation, with vesting contingent on continued service.

Summary

• Juliet Tammenoms Bakker, a Director of RxSight, Inc. (RXST), is scheduled to acquire 10,752 restricted stock units (RSUs) on June 3, 2025.
• Each RSU represents a contingent right to receive one share of RxSight, Inc. Common Stock.
• The RSUs are slated to vest 100% on the earlier of the one-year anniversary of the grant date (June 3, 2025) or the date immediately prior to the next annual meeting of stockholders following the grant date, provided she continues to serve as an Outside Director.
• Following this planned transaction, Ms. Bakker will directly own 48,146 shares of Common Stock and indirectly own 1,548 shares through a trust where she serves as Investment Trustee.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates a routine, pre-planned equity compensation grant to a director, which aligns her interests with shareholders and suggests stability in corporate governance. It's not highly impactful but is a standard positive signal of director retention and alignment.

Positives

• The grant of restricted stock units to a director aligns her financial interests with long-term shareholder value through equity compensation.
• The specified vesting schedule encourages continued commitment and service from the director, promoting stability in corporate governance.

Negatives

• No specific negatives are identified in this routine compensation filing.

Risks

• The vesting of the restricted stock units is contingent on the Reporting Person's continued service as an Outside Director, meaning the shares could be forfeited if her service ceases before the vesting conditions are met.

Future Outlook

The document indicates a future equity grant scheduled for June 3, 2025, which is part of the company's ongoing equity incentive plan for its directors, aligning future compensation with company performance and continued service.

Industry Context

This Form 4 filing reflects a standard practice in the medical technology and ophthalmology device industry, where public companies use equity compensation, such as restricted stock units, to attract, retain, and incentivize independent directors by aligning their interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The acquisition of 10,752 restricted stock units by Director Juliet Tammenoms Bakker from RxSight, Inc. is a related-party transaction as it involves compensation from the company to a member of its board of directors.
• The indirect ownership of 1,548 shares held by a trust where the Reporting Person is the Investment Trustee also represents a related-party interest.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of shareholders, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• The 10,752 restricted stock units are scheduled to be granted to Director Juliet Tammenoms Bakker on June 3, 2025.
• The granted RSUs will vest 100% on the earlier of the one-year anniversary of the grant date (June 3, 2025) or the date immediately prior to the next annual meeting of stockholders following the grant date, subject to continued service.

Key Dates

Recommendation

Keywords

RxSight, RXST, Form 4, SEC filing, Restricted Stock Units, RSU, Director compensation, Insider transaction, Equity incentive plan, Stock grant, Corporate governance